219 related articles for article (PubMed ID: 33601488)
1. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
2. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
3. [Progress on clinical trials of common gastrointestinal cancer drugs in China from 2012 to 2021].
Huang HY; Wu DW; Zhu Q; Yu Y; Wang HX; Wang J; Ga M; Meng XY; Du JT; Miao SM; Zhao ZX; Wang X; Shang P; Guo MJ; Liu LH; Tang Y; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):276-281. PubMed ID: 35316878
[No Abstract] [Full Text] [Related]
4. Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution.
Huang H; Tang Y; Wu D; Meng X; Wang S; Wang J; Yu Y; Fang Y; Fang H; Zhu Q; Li N; Xu B; Sun Y; He J
BMC Geriatr; 2023 Mar; 23(1):199. PubMed ID: 36997858
[TBL] [Abstract][Full Text] [Related]
5. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
6. Recent landscape and trends for industry-sponsored pediatric clinical trials in China from 2013 to 2022.
Liu C; Liu Y; Ou L; Qi Y; Zhang J
Pediatr Investig; 2024 Mar; 8(1):12-20. PubMed ID: 38516137
[TBL] [Abstract][Full Text] [Related]
7. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
8. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
[TBL] [Abstract][Full Text] [Related]
9. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.
Mehta HB; Ehrhardt S; Moore TJ; Segal JB; Alexander GC
BMJ Open; 2020 Jun; 10(6):e039978. PubMed ID: 32518212
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of clinical trials of new oncology drugs approved in China.
Yang J; Yang J; Hu YJ
Cancer; 2024 Mar; 130(5):671-682. PubMed ID: 37985356
[TBL] [Abstract][Full Text] [Related]
13. Rapid advances in research on and development of anticancer drugs in China.
Yao X; Du N; Hu S; Wang L; Gao J
Biosci Trends; 2019 Nov; 13(5):461-463. PubMed ID: 31511442
[TBL] [Abstract][Full Text] [Related]
14. [The development and main achievements of clinical trials for anti-cancer investigational new drug in the past 60 years in China (1960-2020)].
Shi YK; Sun Y
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):696-706. PubMed ID: 34289564
[TBL] [Abstract][Full Text] [Related]
15. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
Hsiue EH; Moore TJ; Alexander GC
Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
[TBL] [Abstract][Full Text] [Related]
16. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
17. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Association of trial registration with the results and conclusions of published trials of new oncology drugs.
Rasmussen N; Lee K; Bero L
Trials; 2009 Dec; 10():116. PubMed ID: 20015404
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.
Green AK; Curry M; Trivedi N; Bach PB; Mailankody S
JAMA Netw Open; 2021 Feb; 4(2):e210030. PubMed ID: 33625507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]